Relyea Zuckerberg Hanson LLC Takes $243,000 Position in Amarin Co. plc (NASDAQ:AMRN)

Relyea Zuckerberg Hanson LLC bought a new stake in Amarin Co. plc (NASDAQ:AMRN) in the fourth quarter, Holdings Channel reports. The institutional investor bought 11,318 shares of the biopharmaceutical company’s stock, valued at approximately $243,000.

Several other large investors have also made changes to their positions in AMRN. Valeo Financial Advisors LLC raised its holdings in shares of Amarin by 23,330.0% in the third quarter. Valeo Financial Advisors LLC now owns 2,343 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 2,333 shares during the last quarter. Endurance Wealth Management Inc. raised its holdings in shares of Amarin by 66.7% in the third quarter. Endurance Wealth Management Inc. now owns 2,500 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 1,000 shares during the last quarter. Lindbrook Capital LLC raised its holdings in shares of Amarin by 118.0% in the third quarter. Lindbrook Capital LLC now owns 4,360 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 2,360 shares during the last quarter. Kistler Tiffany Companies LLC raised its holdings in shares of Amarin by 37.0% in the fourth quarter. Kistler Tiffany Companies LLC now owns 3,700 shares of the biopharmaceutical company’s stock valued at $79,000 after buying an additional 1,000 shares during the last quarter. Finally, NEXT Financial Group Inc raised its holdings in shares of Amarin by 17.1% in the third quarter. NEXT Financial Group Inc now owns 7,670 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 1,120 shares during the last quarter. 52.79% of the stock is owned by institutional investors and hedge funds.

Shares of Amarin stock opened at $19.40 on Thursday. Amarin Co. plc has a 52-week low of $13.76 and a 52-week high of $26.12. The company has a quick ratio of 3.45, a current ratio of 3.69 and a debt-to-equity ratio of 0.02. The company’s 50-day simple moving average is $21.36 and its 200-day simple moving average is $18.45. The firm has a market cap of $6.90 billion, a price-to-earnings ratio of -49.74 and a beta of 1.05.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Amarin had a negative net margin of 17.42% and a negative return on equity of 26.67%. The business had revenue of $112.40 million for the quarter, compared to analyst estimates of $110.04 million. During the same period in the previous year, the business posted ($0.08) earnings per share. The business’s revenue was up 104.4% compared to the same quarter last year. Equities research analysts anticipate that Amarin Co. plc will post -0.1 EPS for the current year.

In other Amarin news, CEO John F. Thero sold 274,454 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $20.91, for a total transaction of $5,738,833.14. Also, CEO John F. Thero sold 475,546 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $24.02, for a total transaction of $11,422,614.92. Insiders have sold 788,600 shares of company stock worth $18,088,620 over the last 90 days. 2.75% of the stock is currently owned by company insiders.

AMRN has been the subject of a number of research reports. Citigroup cut shares of Amarin from a “buy” rating to a “neutral” rating in a report on Wednesday, November 27th. BidaskClub lowered shares of Amarin from a “hold” rating to a “sell” rating in a research note on Friday, January 10th. Stifel Nicolaus reiterated a “hold” rating on shares of Amarin in a research note on Tuesday, January 7th. Leerink Swann reiterated a “buy” rating and set a $29.00 price target on shares of Amarin in a research note on Friday, December 13th. Finally, JPMorgan Chase & Co. began coverage on shares of Amarin in a research note on Monday, January 6th. They set a “neutral” rating and a $22.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $27.23.

About Amarin

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

Recommended Story: VIX – Volatility Index

Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Co. plc (NASDAQ:AMRN).

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.